MESO-Rx
Anabolic Steroids
Can touching a barbell in the gym get you sick with the coronavirus?
- Thread starter Michael Scally MD
- Start date
Villain
Member
Death rates in 2020 the same or even less than 2018. Here’s the real pandemic
www.cnn.com
In Japan, more people died from suicide last month than from Covid in all of 2020
More people died from suicide in Japan in October than succumbed to Covid-19 all year. And more women are taking their own lives, as they lose part-time work and take on the bulk of family responsibilities at home.
What is your problem? Are you really this fucking stupid, or just an asshole? For anyone to deny this is real at this point is insane. You can keep spouting off your endless bullshit, but the more you say it doesn't make it any more true. I see this shit first hand every day, and its insulting to see complete assholes like you continue to downplay it. We have built 4 new ICUs where I work, and they are are now full within 2 weeks. All critically ill covid patients. You think people that see this shit first hand are lying? You don't know a fucking thing, keep being a prick.Death rates in 2020 the same or even less than 2018. Here’s the real pandemic
In Japan, more people died from suicide last month than from Covid in all of 2020
More people died from suicide in Japan in October than succumbed to Covid-19 all year. And more women are taking their own lives, as they lose part-time work and take on the bulk of family responsibilities at home.
Its scary that there are so many people with such conflicting opinions. How can something so black and white have so much grey?
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study
• Primary efficacy analysis of the Phase 3 COVE study of mRNA-1273 involving 30,000 participants included 196 cases of COVID-19, of which 30 cases were severe
• Vaccine efficacy against COVID-19 was 94.1%; vaccine efficacy against severe COVID-19 was 100%
• mRNA-1273 continues to be generally well tolerated; no serious safety concerns identified to date
• Phase 3 COVE Study has exceeded 2 months of median follow-up post vaccination as required by the U.S. FDA for Emergency Use Authorization (EUA)
• Moderna plans today to request EUA from the U.S. FDA, to apply for a conditional marketing authorization with the European Medicines Agency (EMA) and to progress with the rolling reviews, which have already been initiated with international regulatory agencies
• FDA has told Company to expect VRBPAC meeting for mRNA-1273 likely on December 17, 2020
The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. Vaccine efficacy has been demonstrated at the first interim analysis with a total of 95 cases based on the pre-specified success criterion on efficacy.
Today’s primary analysis was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus 11 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.1%.
A secondary endpoint analyzed severe cases of COVID-19 and included 30 severe cases (as defined in the study protocol) in this analysis. All 30 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. There was one COVID-19-related death in the study to date, which occurred in the placebo group.
Efficacy was consistent across age, race and ethnicity, and gender demographics. The 196 COVID-19 cases included 33 older adults (ages 65+) and 42 participants identifying as being from diverse communities (including 29 Hispanic or LatinX, 6 Black or African Americans, 4 Asian Americans and 3 multiracial participants).
The safety profile of the Phase 3 study of mRNA-1273 was previously described on November 16. A continuous review of safety data is ongoing and no new serious safety concerns have been identified by the Company. Based on prior analysis, the most common solicited adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.
The Company will submit data from the Phase 3 COVE study to a peer-reviewed publication.
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study
• Primary efficacy analysis of the Phase 3 COVE study of mRNA-1273 involving 30,000 participants included 196 cases of COVID-19, of which 30 cases were severe
• Vaccine efficacy against COVID-19 was 94.1%; vaccine efficacy against severe COVID-19 was 100%
• mRNA-1273 continues to be generally well tolerated; no serious safety concerns identified to date
• Phase 3 COVE Study has exceeded 2 months of median follow-up post vaccination as required by the U.S. FDA for Emergency Use Authorization (EUA)
• Moderna plans today to request EUA from the U.S. FDA, to apply for a conditional marketing authorization with the European Medicines Agency (EMA) and to progress with the rolling reviews, which have already been initiated with international regulatory agencies
• FDA has told Company to expect VRBPAC meeting for mRNA-1273 likely on December 17, 2020
The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. Vaccine efficacy has been demonstrated at the first interim analysis with a total of 95 cases based on the pre-specified success criterion on efficacy.
Today’s primary analysis was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus 11 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.1%.
A secondary endpoint analyzed severe cases of COVID-19 and included 30 severe cases (as defined in the study protocol) in this analysis. All 30 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. There was one COVID-19-related death in the study to date, which occurred in the placebo group.
Efficacy was consistent across age, race and ethnicity, and gender demographics. The 196 COVID-19 cases included 33 older adults (ages 65+) and 42 participants identifying as being from diverse communities (including 29 Hispanic or LatinX, 6 Black or African Americans, 4 Asian Americans and 3 multiracial participants).
The safety profile of the Phase 3 study of mRNA-1273 was previously described on November 16. A continuous review of safety data is ongoing and no new serious safety concerns have been identified by the Company. Based on prior analysis, the most common solicited adverse reactions included injection site pain, fatigue, myalgia, arthralgia, headache, and erythema/redness at the injection site. Solicited adverse reactions increased in frequency and severity in the mRNA-1273 group after the second dose.
The Company will submit data from the Phase 3 COVE study to a peer-reviewed publication.
Villain
Member
Again, fuck you bitch. Look at the fucking death toll you fucking piece of shit - it’s the same. Got that??? The death toll of 2020 is the SAME as 2018, pre Covid! What don’t you understand you fucking cuck? Oh, and look at the source, you fuckwit - even a liberal rag like CNN reported this.
Last edited:
Gentleman is there not a chance both are correct? Death tolls may be close, many people who died from Covid very probably would have died anyways. However, look at the death rate, like 1-2%, that is not the ultimate problem with hospitals. Look at the hospitalization rate. Many people don’t die, that doesn’t mean they aren’t going to the hospital, receiving treatment, taking up beds, and then going home. The problem is that no hospitals, some people who would be getting treatment for Covid AND other things and go home alive, will be unable to receive that treatment and some of those will die. If I am thinking correctly, the problem is less about the death rate and more about the hospitalization rate, which will eventually effect death rates for Covid and other diseases as well as drive hospital workers to the breaking point. Restrictions, not shutdowns, are ways to keep hospitals and businesses open and running. I am as anti shutdown/lockdown/stay at home mandatory as a person can get but I am also pro temporary restrictions so we can keep our jobs and our hospitals and health care workers and get treatments we need. I see restrictions as a pathway back to eventual normalcy, which we will get to. There is no way this will become a way of life, but I think temporary restrictions are the way to get back to real normalcy sooner. Just a very uneducated opinion.
I am thankful to those who fight against blatant fear mongering but also thankful for those who present the truth of a real health crisis. Both sides are needed to properly navigate this. Decisions made by fear are often bad. And yet decisions not made with caution and acknowledgement of real danger are also foolish. Thanks villain and lilhawk for helping me think about this and hopefully live life to the fullest, and yet responsibly, during this time.
I am thankful to those who fight against blatant fear mongering but also thankful for those who present the truth of a real health crisis. Both sides are needed to properly navigate this. Decisions made by fear are often bad. And yet decisions not made with caution and acknowledgement of real danger are also foolish. Thanks villain and lilhawk for helping me think about this and hopefully live life to the fullest, and yet responsibly, during this time.
Gentleman is there not a chance both are correct? Death tolls may be close, many people who died from Covid very probably would have died anyways. However, look at the death rate, like 1-2%, that is not the ultimate problem with hospitals. Look at the hospitalization rate. Many people don’t die, that doesn’t mean they aren’t going to the hospital, receiving treatment, taking up beds, and then going home. The problem is that no hospitals, some people who would be getting treatment for Covid AND other things and go home alive, will be unable to receive that treatment and some of those will die.
[OA] Effective control of SARS-CoV-2 transmission in Wanzhou, China
The effectiveness of control measures to contain coronavirus disease 2019 (COVID-19) in Wanzhou, China was assessed. Epidemiological data were analyzed for 183 confirmed COVID-19 cases and their close contacts from five generations of transmission of severe acute respiratory syndrome coronavirus 2 throughout the entire COVID-19 outbreak in Wanzhou. Approximately 67.2% and 32.8% of cases were symptomatic and asymptomatic, respectively. Asymptomatic and presymptomatic transmission accounted for 75.9% of the total recorded transmission.
The reproductive number was 1.64 (95% confidence interval: 1.16–2.40) for G1-to-G2 transmission, decreasing to 0.31–0.39 in later generations, concomitant with implementation of rigorous control measures. Substantially higher infection risk was associated with contact within 5 d after the infectors had been infected, frequent contact and ≥8 h of contact duration.
The spread of COVID-19 was effectively controlled in Wanzhou by breaking the transmission chain through social distancing, extensive contact tracing, mass testing and strict quarantine of close contacts.
Shi, Q., Hu, Y., Peng, B. et al. Effective control of SARS-CoV-2 transmission in Wanzhou, China. Nat Med (2020). https://doi.org/10.1038/s41591-020-01178-5
The effectiveness of control measures to contain coronavirus disease 2019 (COVID-19) in Wanzhou, China was assessed. Epidemiological data were analyzed for 183 confirmed COVID-19 cases and their close contacts from five generations of transmission of severe acute respiratory syndrome coronavirus 2 throughout the entire COVID-19 outbreak in Wanzhou. Approximately 67.2% and 32.8% of cases were symptomatic and asymptomatic, respectively. Asymptomatic and presymptomatic transmission accounted for 75.9% of the total recorded transmission.
The reproductive number was 1.64 (95% confidence interval: 1.16–2.40) for G1-to-G2 transmission, decreasing to 0.31–0.39 in later generations, concomitant with implementation of rigorous control measures. Substantially higher infection risk was associated with contact within 5 d after the infectors had been infected, frequent contact and ≥8 h of contact duration.
The spread of COVID-19 was effectively controlled in Wanzhou by breaking the transmission chain through social distancing, extensive contact tracing, mass testing and strict quarantine of close contacts.
Shi, Q., Hu, Y., Peng, B. et al. Effective control of SARS-CoV-2 transmission in Wanzhou, China. Nat Med (2020). https://doi.org/10.1038/s41591-020-01178-5
[OA] Be Aware of Droplets and Bubbles
Manna A. Annals Graphic Medicine - Be Aware of Droplets and Bubbles. Annals of internal medicine 2020. https://www.acpjournals.org/doi/abs/10.7326/G20-0114
Manna A. Annals Graphic Medicine - Be Aware of Droplets and Bubbles. Annals of internal medicine 2020. https://www.acpjournals.org/doi/abs/10.7326/G20-0114
Similar threads
